Lidocaine for the management of pain

Delivery Platform
Date Started: 2020-02-04
Progress - Discovery - Not Recruiting

test

Study Site:

Medlab, 66 McCauley Street, Alexandria, NSW 2015, Australia

ABOUT TRIAL:

The program investigates a nanoparticle Lidocaine for enhanced efficacy over standard tablet form.

Lidocaine is a medication used to numb tissue in a specific area. It is also used to treat ventricular tachycardia and to perform nerve blocks. Dosage forms include IV, gels, creams, sprays, drops, and patches. IV holds the greatest onset of action with other forms reported to take 30-60 minutes. Lidocaine has been shown to be successful in controlling pain where other agents have failed. The opioid-sparing properties of lidocaine added to its analgesic properties make lidocaine a viable option for pain control in opioid-dependent patients.

Sides effects are well documented, with some requiring urgent medical attention.

The program looks at improving onset times for topical and oro-buccal applications increasing use availability in dental and general practice.